Aminopyridines for the treatment of cerebellar and ocular motor disorders

Progress in Brain Research
M StruppThomas Brandt

Abstract

Downbeat nystagmus (DBN) is the most frequent form of acquired persisting fixation nystagmus. It is hypothesized to occur when physiological inhibitory cerebellar input, namely of the flocculus, to the vestibular nuclei is inhibited. The second most frequent form of acquired nystagmus is upbeat nystagmus (UBN). UBN is probably caused by an imbalance of vertical vestibulo-ocular reflex tone. GABA-ergic substances like baclofen have been used to treat DBN and UBN, but they have had only moderate success. Animal experiments have shown that aminopyridines [3,4-diaminopyridine (3,4-DAP) and 4-aminopyridine (4-AP)], nonselective blockers of the Kv family of voltage-gated potassium channels, increase Purkinje-cell (PC) excitability. It was assumed that such enhancement of PC activity could restore to normal levels the inhibitory influence of the cerebellar cortex on vertical eye movements. On the basis of these assumptions, we evaluated the efficacy and underlying mechanisms of aminopyridines in DBN and UBN as well as in another cerebellar disorder with an impaired PC function: episodic ataxia type 2 (EA2), which is caused by mutations of the PQ-calcium channel. In a placebo-controlled trial on 17 patients we demonstrated that 3,4-DAP...Continue Reading

Citations

May 28, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Karina Alviña, Kamran Khodakhah
May 28, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Karina Alviña, Kamran Khodakhah
May 7, 2014·Multiple Sclerosis International·Luca ProsperiniCarlo Pozzilli
Sep 2, 2016·Therapeutic Advances in Neurological Disorders·Hiroshi Mitoma, Mario Manto
Mar 6, 2018·The Cochrane Database of Systematic Reviews·Fiona J RoweHelen Rodgers
Nov 6, 2009·The Cerebellum·Antoni Matilla-DueñasPilar Latorre
Nov 26, 2010·Current Opinion in Neurology·Caroline Tilikete, Alain Vighetto
Jul 16, 2009·Expert Opinion on Pharmacotherapy·Rebecca Jane McLean, Irene Gottlob
Feb 23, 2012·Current Neurology and Neuroscience Reports·Rebecca Jane McLeanFrank Antony Proudlock
Jul 26, 2013·Journal of Neurology·Aasef G ShaikhDominik Straumann
Jun 12, 2014·Movement Disorders Clinical Practice·Harini Sarva, Vicki Lynn Shanker
Nov 26, 2010·Journal of Neuro-ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society·Matthew J Thurtell, R John Leigh
Apr 24, 2015·Annals of the New York Academy of Sciences·Michael StruppThomas Brandt
Mar 25, 2011·Journal of Neurology·Roman SchnieppKlaus Jahn
Dec 11, 2019·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Luca ProsperiniCarlo Pozzilli
Oct 7, 2015·BMC Complementary and Alternative Medicine·Chung-Hung ShihWun-Chang Ko
Aug 31, 2021·Current Opinion in Ophthalmology·Tu M TranCollin M McClelland
Nov 23, 2021·Frontiers in Neurology·Taylor J BoschArun Singh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxia

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Related Papers

Therapeutic Advances in Neurological Disorders
M Strupp, T Brandt
Journal of Neuro-ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society
R KallaM Strupp
© 2022 Meta ULC. All rights reserved